Floatz logo

TELITACICEPT

Moderate and Severe RheumatoId Arthritis

RemeGen Co., Ltd.protein_peptidePhase 3Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

20 Active assets in the Moderate and Severe RheumatoId Arthritis cohort.

Asset / SponsorPhaseRating
Naltrexone
Truway Health, Inc.
Phase 4BBB
METHOTREXATE
National Institute of Allergy and Infectious Diseases (NIAID)
Phase 3BB
IBUPROFEN
Amgen
Phase 3BB
Buprenorphine
Mundipharma Pte Ltd.
Phase 4BB
Tocilizumab
Hoffmann-La Roche
Phase 3BB

View all 38 →

Same molecule, other indications

TELITACICEPT is also rated in:

relapsing-remitting multiple sclerosisDormant
CC
Indicative ·
42 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →